ReviewCurrent cardiology reports2018

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?

Yixing Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.